1. Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy.

    American Journal of Clinical Oncology 38(4):377 (2015) PMID 24192805

    Doxorubicin is associated with a cumulative dose-dependent nonischemic cardiomyopathy. Cardiac magnetic resonance imaging (cMRI) is able to examine both structural and functional components of the myocardium. Our aim was to assess the myocardial changes in non-Hodgkin lymphoma patients undergoin...
  2. Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades.

    Clinical Lymphoma Myeloma and Leukemia 15(7):409 (2015) PMID 25816932

    Understanding the mortality patterns of patients with lymphoma and myeloma, who have undergone autologous hematopoietic stem cell transplantation (ASCT) might identify improvement opportunities. The present retrospective study included patients with lymphoma and myeloma, aged ≥ 18 years, who had...
  3. The aggressive peripheral T-cell lymphomas: 2015.

    American Journal of Hematology 90(7):665 (2015) PMID 26031230

    T-cell lymphomas make up approximately 10%-15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia. The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the World Health Organization classifi...
  4. Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?

    Haematologica 100(7):853 (2015) PMID 26130511 PMCID PMC4486218

  5. Controversies in the treatment of early-stage Hodgkin's lymphoma.

    New England Journal of Medicine 372(17):1667 (2015) PMID 25901431

  6. Classification of non-Hodgkin lymphoma in Algeria according to the World Health Organization classification.

    Leukemia & Lymphoma 56(4):965 (2015) PMID 25012941

    The relative distribution of non-Hodgkin lymphoma (NHL) subtypes differs markedly around the world. The aim of this study was to report this distribution in Algeria. A panel of four hematopathologists classified 197 consecutive cases according to the World Health Organization classification, inc...
  7. Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder.

    Journal of the National Comprehensive Cancer Ne... 13(3):281 (2015) PMID 25736004

    Essential thrombocythemia is well-known to transform to other myeloid disorders, such as leukemia; however, the risk for development of lymphoma is not as well studied. This case report discusses a 76-year-old man with a history of prefibrotic post-essential thrombocythemia myelofibrosis on ruxo...
  8. Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder.

    Journal of the National Comprehensive Cancer Ne... 13(3):281 (2015) PMID 25736004

    Essential thrombocythemia is well-known to transform to other myeloid disorders, such as leukemia; however, the risk for development of lymphoma is not as well studied. This case report discusses a 76-year-old man with a history of prefibrotic post-essential thrombocythemia myelofibrosis on ruxo...
  9. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

    Blood 125(7):1137 (2015) PMID 25498913

    We studied the global microRNA (miRNA) expression in diffuse large B-cell lymphoma (DLBCL; n = 79), Burkitt lymphoma (BL; n = 36), primary mediastinal B-cell lymphoma (PMBL; n = 12), B-cell lines (n = 11), and normal subsets of naïve B cells, centroblasts (CBs), and peripheral blood B cells alon...
  10. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

    Blood 125(7):1137 (2015) PMID 25498913 PMCID PMC4326773

    We studied the global microRNA (miRNA) expression in diffuse large B-cell lymphoma (DLBCL; n = 79), Burkitt lymphoma (BL; n = 36), primary mediastinal B-cell lymphoma (PMBL; n = 12), B-cell lines (n = 11), and normal subsets of naïve B cells, centroblasts (CBs), and peripheral blood B cells alon...
  11. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

    Blood 125(7):1137 (2015) PMID 25498913 PMCID PMC4326773

    We studied the global microRNA (miRNA) expression in diffuse large B-cell lymphoma (DLBCL; n = 79), Burkitt lymphoma (BL; n = 36), primary mediastinal B-cell lymphoma (PMBL; n = 12), B-cell lines (n = 11), and normal subsets of naïve B cells, centroblasts (CBs), and peripheral blood B cells alon...
  12. Regulatory and clinical considerations for biosimilar oncology drugs.

    The Lancet Oncology 15(13):e594 (2014) PMID 25456378

    Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biolog...
  13. Regulatory and clinical considerations for biosimilar oncology drugs.

    The Lancet Oncology 15(13):e594 (2014) PMID 25456378

    Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biolog...
  14. Regulatory and clinical considerations for biosimilar oncology drugs.

    The Lancet Oncology 15(13):e594 (2014) PMID 25456378

    Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biolog...
  15. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.

    Cancer 120(14):2122 (2014) PMID 24711253

    The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. In total, 241 patients who were newly diagnosed with c...
  16. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.

    Cancer 120(14):2122 (2014) PMID 24711253

    The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. In total, 241 patients who were newly diagnosed with c...
  17. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.

    Journal of the National Comprehensive Cancer Ne... 12(7):963 (2014) PMID 24994916

    Philadelphia chromosome-positive acute myeloid leukemia (Ph(+)-AML) has a poor response to anthracycline- and cytarabine-containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short...
  18. Lymphoma diagnosis at an academic centre: rate of revision and impact on patient care.

    British Journal of Haematology 166(2):202 (2014) PMID 24697285

    Few studies have examined the value of a mandatory second review of outside pathology material for haematological malignancies. Therefore, we compared diagnoses on biopsies referred to an academic medical centre to determine the rate and therapeutic impact of revised diagnoses resulting from a s...
  19. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.

    Journal of the National Comprehensive Cancer Ne... 12(7):963 (2014) PMID 24994916

    Philadelphia chromosome-positive acute myeloid leukemia (Ph(+)-AML) has a poor response to anthracycline- and cytarabine-containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short...
  20. Lymphoma diagnosis at an academic centre: rate of revision and impact on patient care.

    British Journal of Haematology 166(2):202 (2014) PMID 24697285

    Few studies have examined the value of a mandatory second review of outside pathology material for haematological malignancies. Therefore, we compared diagnoses on biopsies referred to an academic medical centre to determine the rate and therapeutic impact of revised diagnoses resulting from a s...